Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

2GVL

Crystal Structure of Murine NMPRTase

2GVL の概要
エントリーDOI10.2210/pdb2gvl/pdb
分子名称Nicotinamide phosphoribosyltransferase (2 entities in total)
機能のキーワードvisfatin, pbef, nmprtase, cancer, fk866, transferase
由来する生物種Mus musculus (house mouse)
細胞内の位置Cytoplasm: Q99KQ4
タンパク質・核酸の鎖数2
化学式量合計111137.13
構造登録者
Khan, J.A.,Tao, X.,Tong, L. (登録日: 2006-05-02, 公開日: 2006-07-25, 最終更新日: 2024-10-30)
主引用文献Khan, J.A.,Tao, X.,Tong, L.
Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents.
Nat.Struct.Mol.Biol., 13:582-588, 2006
Cited by
PubMed Abstract: Nicotinamide phosphoribosyltransferase (NMPRTase) has a crucial role in the salvage pathway of NAD+ biosynthesis, and a potent inhibitor of NMPRTase, FK866, can reduce cellular NAD+ levels and induce apoptosis in tumors. We have determined the crystal structures at up to 2.1-A resolution of human and murine NMPRTase, alone and in complex with the reaction product nicotinamide mononucleotide or the inhibitor FK866. The structures suggest that Asp219 is a determinant of substrate specificity of NMPRTase, which is confirmed by our mutagenesis studies. FK866 is bound in a tunnel at the interface of the NMPRTase dimer, and mutations in this binding site can abolish the inhibition by FK866. Contrary to current knowledge, the structures show that FK866 should compete directly with the nicotinamide substrate. Our structural and biochemical studies provide a starting point for the development of new anticancer agents.
PubMed: 16783377
DOI: 10.1038/nsmb1105
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.1 Å)
構造検証レポート
Validation report summary of 2gvl
検証レポート(詳細版)ダウンロードをダウンロード

252456

件を2026-04-22に公開中

PDB statisticsPDBj update infoContact PDBjnumon